These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 35316551)

  • 41. Anaphylaxis and Related Events Following COVID-19 Vaccination: A Systematic Review.
    Paul P; Janjua E; AlSubaie M; Ramadorai V; Mushannen B; Vattoth AL; Khan W; Bshesh K; Nauman A; Mohammed I; Bouhali I; Khalid M; Zakaria D
    J Clin Pharmacol; 2022 Nov; 62(11):1335-1349. PubMed ID: 35794852
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cutaneous reactions to COVID-19 vaccines: A review.
    Tan SW; Tam YC; Pang SM
    JAAD Int; 2022 Jun; 7():178-186. PubMed ID: 35194586
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults - United States, September 22, 2021-February 6, 2022.
    Hause AM; Baggs J; Marquez P; Myers TR; Su JR; Blanc PG; Gwira Baumblatt JA; Woo EJ; Gee J; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(7):249-254. PubMed ID: 35176008
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Delayed Localized Hypersensitivity Reactions to the Moderna COVID-19 Vaccine: A Case Series.
    Johnston MS; Galan A; Watsky KL; Little AJ
    JAMA Dermatol; 2021 Jun; 157(6):716-720. PubMed ID: 33978670
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Description of Frequencies of Reported Adverse Events Following Immunization Among Four Different COVID-19 Vaccine Brands.
    Kant A; Jansen J; van Balveren L; van Hunsel F
    Drug Saf; 2022 Apr; 45(4):319-331. PubMed ID: 35314943
    [TBL] [Abstract][Full Text] [Related]  

  • 47. New Onset and Exacerbations of Psoriasis Following COVID-19 Vaccines: A Systematic Review.
    Wu PC; Huang IH; Wang CW; Tsai CC; Chung WH; Chen CB
    Am J Clin Dermatol; 2022 Nov; 23(6):775-799. PubMed ID: 36048409
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tolerability of COVID-19 Infection and Messenger RNA Vaccination Among Patients With a History of Kawasaki Disease.
    Beckley M; Olson AK; Portman MA
    JAMA Netw Open; 2022 Aug; 5(8):e2226236. PubMed ID: 35960521
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial.
    Oda Y; Kumagai Y; Kanai M; Iwama Y; Okura I; Minamida T; Yagi Y; Kurosawa T; Greener B; Zhang Y; Walson JL
    Lancet Infect Dis; 2024 Apr; 24(4):351-360. PubMed ID: 38141632
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Side effects of Pfizer/BioNTech (BNT162b2) COVID-19 vaccine reported by the Birzeit University community.
    Abukhalil AD; Shatat SS; Abushehadeh RR; Al-Shami N; Naseef HA; Rabba A
    BMC Infect Dis; 2023 Jan; 23(1):5. PubMed ID: 36604613
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A Systematic Review of Histopathologic Surveys on Mucocutaneous Biopsies in Patients Developed COVID-19 Vaccine-Related Dermatologic Manifestations.
    Salehi S; Sadeghi S; Kalantari Y; Goodarzi A
    Am J Dermatopathol; 2023 Jan; 45(1):1-27. PubMed ID: 36484603
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and safety of COVID-19 vaccines.
    Graña C; Ghosn L; Evrenoglou T; Jarde A; Minozzi S; Bergman H; Buckley BS; Probyn K; Villanueva G; Henschke N; Bonnet H; Assi R; Menon S; Marti M; Devane D; Mallon P; Lelievre JD; Askie LM; Kredo T; Ferrand G; Davidson M; Riveros C; Tovey D; Meerpohl JJ; Grasselli G; Rada G; Hróbjartsson A; Ravaud P; Chaimani A; Boutron I
    Cochrane Database Syst Rev; 2022 Dec; 12(12):CD015477. PubMed ID: 36473651
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Adverse effects following COVID-19 vaccination in Iran.
    Babaee E; Amirkafi A; Tehrani-Banihashemi A; SoleimanvandiAzar N; Eshrati B; Rampisheh Z; Asadi-Aliabadi M; Nojomi M
    BMC Infect Dis; 2022 May; 22(1):476. PubMed ID: 35585518
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Analysis of hematologic adverse events reported to a national surveillance system following COVID-19 bivalent booster vaccination.
    Jacobs JW; Booth GS; Adkins BD
    Ann Hematol; 2023 Apr; 102(4):955-959. PubMed ID: 36795118
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Adverse Events of COVID-19 Vaccines in the United States: Temporal and Spatial Analysis.
    Li Y; Li J; Dang Y; Chen Y; Tao C
    JMIR Public Health Surveill; 2024 Jul; 10():e51007. PubMed ID: 39008362
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Global prevalence and clinical manifestations of cutaneous adverse reactions following COVID-19 vaccination: A systematic review and meta-analysis.
    Washrawirul C; Triwatcharikorn J; Phannajit J; Ullman M; Susantitaphong P; Rerknimitr P
    J Eur Acad Dermatol Venereol; 2022 Nov; 36(11):1947-1968. PubMed ID: 35666609
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tree-based data mining for safety assessment of first COVID-19 booster doses in the Vaccine Safety Datalink.
    Katherine Yih W; Daley MF; Duffy J; Fireman B; McClure D; Nelson J; Qian L; Smith N; Vazquez-Benitez G; Weintraub E; Williams JTB; Xu S; Maro JC
    Vaccine; 2023 Jan; 41(2):460-466. PubMed ID: 36481108
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Adverse reactions to the first and second doses of Pfizer-BioNTech COVID-19 vaccine among healthcare workers.
    Maruyama A; Sawa T; Teramukai S; Katoh N
    J Infect Chemother; 2022 Jul; 28(7):934-942. PubMed ID: 35361536
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A prospective multicenter study on cutaneous reactions reported after Sinopharm COVID-19 vaccination.
    Shawky A; Elrewiny EM; Gharib K; Sallam M; Mansour M; Rageh MA
    Int J Dermatol; 2023 Feb; 62(2):221-224. PubMed ID: 35959522
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cutaneous adverse reactions following COVID-19 vaccinations: A systematic review and meta-analysis.
    Shafie'ei M; Jamali M; Akbari Z; Sarvipour N; Ahmadzade M; Ahramiyanpour N
    J Cosmet Dermatol; 2022 Sep; 21(9):3636-3650. PubMed ID: 35861631
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.